GRAIL Past Earnings Performance
Past criteria checks 0/6
GRAIL's earnings have been declining at an average annual rate of -42.9%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 72.6% per year.
Key information
-42.9%
Earnings growth rate
-94.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 72.6% |
| Return on equity | -81.8% |
| Net Margin | -1,799.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How GRAIL makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 118 | -2,117 | 360 | 348 |
| 30 Jun 24 | 110 | -2,883 | 373 | 360 |
| 31 Mar 24 | 100 | -1,491 | 357 | 354 |
| 31 Dec 23 | 93 | -1,466 | 345 | 339 |
| 01 Jan 23 | 56 | -5,399 | 284 | 330 |
| 02 Jan 22 | 15 | -1,248 | 234 | 283 |
| 30 Jun 21 | 1 | -387 | 172 | 216 |
| 31 Mar 21 | 0 | -350 | 148 | 204 |
| 31 Dec 20 | 0 | -312 | 124 | 193 |
| 30 Sep 20 | 0 | -284 | 113 | 174 |
| 30 Jun 20 | 0 | -264 | 105 | 165 |
| 31 Mar 20 | 0 | -254 | 97 | 165 |
| 31 Dec 19 | 0 | -245 | 89 | 165 |
Quality Earnings: GRAL is currently unprofitable.
Growing Profit Margin: GRAL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GRAL is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year.
Accelerating Growth: Unable to compare GRAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: GRAL has a negative Return on Equity (-81.83%), as it is currently unprofitable.